May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
An In Vitro Examination of Minocycline as a Retinal Neuroprotective Agent
Author Affiliations & Notes
  • D.C. Baptiste
    Pharmacology, Retina & Optic Nerve Research Laboratory, Dalhousie University, Halifax, NS, Canada
  • C.A. Jollimore
    Pharmacology, Retina & Optic Nerve Research Laboratory, Dalhousie University, Halifax, NS, Canada
  • G.M. Seigel
    Ophthalmology, Physiology & Biophysics, University of Buffalo, Buffalo, NY, United States
  • M.E. Kelly
    Pharmacology & Ophthlamology, Retina & Optic Nerve Research Laboratory, Dalhousie University, Halifax, NS, Canada
  • Footnotes
    Commercial Relationships  D.C. Baptiste, None; C.A.B. Jollimore, None; G.M. Seigel, None; M.E.M. Kelly, None.
  • Footnotes
    Support  CIHR MT-13484
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 5222. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D.C. Baptiste, C.A. Jollimore, G.M. Seigel, M.E. Kelly; An In Vitro Examination of Minocycline as a Retinal Neuroprotective Agent . Invest. Ophthalmol. Vis. Sci. 2003;44(13):5222.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To study the efficacy of minocycline, a second generation tetracycline, to reduce cell death in primary rat retinal cultures, an immortalized rat retinal cell line (E1A-NR.3) and a rat phenochromocytoma cell line (PC12) following glutamate excitotoxicity or trophic withdrawal. Methods: Cell viability was measured using a cell lysis technique in primary retinal cultures treated for 24-hours with 100 µM glutamate, with or without the inclusion of minocycline (0.002-200 µM). Each treatment group in separate experiments consisted of triplicate wells. For cell lines deprived of serum for 48-hours (E1A-NR.3), or nerve growth factor (NGF) for 12-hours (PC12), in the presence and absence of minocycline, cell viability was measured using a live/dead assay with acridine orange and ethidium bromide. The effects of minocycline on caspase-3 gene expression were studied using semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). Results: Minocycline, but not tetracycline, protected primary retinal cells from excitotoxic cell death. At doses of 2, 20 and 200 µM, minocycline produced an 59%, 82% and 82% increase in cell survival respectively (p<0.05). Minocycline’s protective actions were also confirmed in the E1A-NR.3 cell line, with increases in cell survival of 23% and 25% (p<0.05) at minocycline doses of 0.02 and 0.2 µM following glutamate-induced excitotoxicity, and 14% and 11% (p<0.01 and p<0.05 respectively) following serum withdrawal. Minocycline, at 0.2 and 2 µM also prevented the cell death associated with NGF withdrawal in differentiated PC12 cells (p<0.01). RT-PCR analysis of apoptotic gene expression in retinal E1A-NR.3 cells following 24-hour serum deprivation revealed that 200 nM minocycline decreases caspase-3 mRNA expression. Conclusions: Minocycline increases cell survival and prevents apoptotic cell death of primary retinal cell cultures, the E1A-NR.3 cell line and PC12 cells following glutamate excitotoxicity or trophic withdrawal. The survival-promoting effects of minocycline are not shared by tetracycline. The neuroprotective properties of minocycline may be attributed to a reduction in pro-apoptotic caspase-3 gene expression.

Keywords: neuroprotection • retinal culture • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×